Aditxt, Inc. (ADTX)
NASDAQ: ADTX · IEX Real-Time Price · USD
2.010
-0.020 (-0.99%)
At close: May 17, 2024, 4:00 PM
2.070
+0.060 (2.99%)
After-hours: May 17, 2024, 7:49 PM EDT
Aditxt Revenue
In the year 2023, Aditxt had annual revenue of $645.18K, a decrease of -30.90%. Revenue in the quarter ending December 31, 2023 was $81.30K, a -56.20% decrease year-over-year.
Revenue (ttm)
$645.18K
Revenue Growth
-30.90%
P/S Ratio
6.23
Revenue / Employee
$13,727
Employees
47
Market Cap
4.02M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 645.18K | -288.54K | -30.90% |
| Dec 31, 2022 | 933.72K | 828.68K | 788.96% |
| Dec 31, 2021 | 105.03K | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Venus Concept | 73.30M |
| SunLink Health Systems | 35.51M |
| ReShape Lifesciences | 8.34M |
| Evoke Pharma | 6.11M |
| Petros Pharmaceuticals | 4.69M |
| Assure Holdings | 255.00K |
| IMAC Holdings | -2.09M |
ADTX News
- 3 days ago - Evofem Biosciences Announces Financial Results for the First Quarter of 2024 - PRNewsWire
- 15 days ago - CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules - Business Wire
- 15 days ago - Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules - Business Wire
- 6 weeks ago - Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) - Business Wire
- 7 weeks ago - Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 - PRNewsWire
- 2 months ago - Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal - PRNewsWire
- 2 months ago - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy - PRNewsWire
- 3 months ago - Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 - PRNewsWire